18F-DCFPyL PSMA PET/CT 在前列腺癌生化复发中的前瞻性研究
结果显示该检查安全性良好,在不同PSA区间均能定位复发灶,且多数患者的治疗决策因此发生改变。
要点
- 18F-DCFPyL PET/CT在前列腺癌生化复发中安全且敏感。
- PSA≥0.4至<0.5即可定位60%的复发灶。
- 87.3%患者的治疗管理计划因该检查发生改变。
核心结论
- 18F-DCFPyL PET/CT对前列腺癌生化复发的定位安全且敏感。
- 该检查改善了转诊肿瘤科医生的决策,并改变了多数患者的治疗管理。
研究设计与样本
- 前瞻性研究纳入前列腺癌根治术后或根治性放疗后生化复发的受试者。
- 受试者接受18F-DCFPyL PET/CT显像,记录病灶定位与数量。
主要发现
- PSA≥0.4至<0.5者60%定位到复发灶,≥0.5至<1.0者为78%,≥1.0至<2.0者为72%,≥2.0者为92%。
- 40.8%受试者仅1个病灶,8.5%有2个病灶,4.6%有3个病灶。
- 病灶数量与PSA水平经ANOVA分析显著相关,但不同病灶数量类别间PSA值重叠较大。
- 总病灶摄取也与PSA水平显著相关。
- 65.5%受试者治疗意图改变,65.5%疾病分期改变,87.3%管理计划改变。
临床怎么用
- 对前列腺癌生化复发患者,可考虑行18F-DCFPyL PET/CT以定位复发灶并指导治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid), a prostate-specific membrane antigen-targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity, and impact on patient management of 18F-DCFPyL in the setting of biochemical recurrence of prostate cancer. Methods: Subjects with prostate cancer and biochemical recurrence after radical prostatectomy or curative-intent radiotherapy were included in this prospective study. The subjects underwent 18F-DCFPyL PET/CT imaging. The localization and number of lesions were recorded. The uptake characteristics of the 5 most active lesions were measured. A pre- and posttest questionnaire was sent to treating physicians to assess the impact on management. Results: One hundred thirty subjects were evaluated. 18F-DCFPyL PET/CT localized recurrent prostate cancer in 60% of cases with a prostate-specific antigen (PSA) level of ≥0.4 to <0.5, 78% with a level of ≥0.5 to <1.0, 72% with a level of ≥1.0 to <2.0, and 92% with a level of ≥2.0. Many subjects had few lesions (1 lesion in 40.8%, 2 in 8.5%, and 3 in 4.6%). The number of lesions was significantly related to PSA by ANOVA, but there was a large overlap in the PSA values for number of lesion categories. Total lesion uptake was also significantly related to PSA level. A change in treatment intent occurred in 65.5% of subjects, disease stage changed in 65.5%, and management plans changed in 87.3%. Twenty-two subjects reported mild adverse events after the scan; all resolved completely. Conclusion:18F-DCFPyL PET/CT is safe and sensitive for the localization of biochemical recurrence of prostate cancer. This test improved decision making for referring oncologists and changed management for most subjects.
引用
- Rousseau E, Wilson D, Lacroix-Poisson F, et al. A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2019. PMID: 30979820. doi:10.2967/jnumed.119.226381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。